T. Rowe Price Investment Management, Inc. Argenx Se Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Argenx Se stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 771,572 shares of ARGX stock, worth $435 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
771,572
Previous 1,924,712
59.91%
Holding current value
$435 Million
Previous $828 Million
49.47%
% of portfolio
0.25%
Previous 0.52%
Shares
9 transactions
Others Institutions Holding ARGX
# of Institutions
400Shares Held
30.9MCall Options Held
376KPut Options Held
489K-
Price T Rowe Associates Inc Baltimore, MD5.82MShares$3.28 Billion0.36% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$1.98 Billion2.99% of portfolio
-
Janus Henderson Group PLC London, X02.48MShares$1.4 Billion0.72% of portfolio
-
Capital World Investors Los Angeles, CA1.7MShares$959 Million0.15% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$699 Million10.11% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $31.2B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...